跳至主要内容
临床试验/NCT07396220
NCT07396220Enrolling By Invitation不适用

Combined Intranasal Esketamine and Brief Cognitive Behavioral Therapy for Suicidal Ideation - A Randomized Controlled Trial

University of California, San Diego1 个研究点 分布在 1 个国家目标入组 56 人开始时间: 2026年1月9日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
Enrolling By Invitation
入组人数
56
试验地点
1
主要终点
Beck Scale for Suicidal Ideation

研究概览

简要总结

The purpose of this study is to examine the effects of combined intranasal esketamine with brief cognitive behavioral therapy for suicide prevention (BCBT-SP) for suicidal ideation (SI) in patients with treatment- resistant depression (TRD). The secondary aim is to identify the biological targets of treatment response using combined transcranial magnetic stimulation and electroencephalography (TMS-EEG). In this project we will recruit patients between the ages of 18 and 70, diagnosed with a major depressive episode with ongoing suicidal ideation present who have failed (or not shown signs of improvement) after at least one prior treatment. The null hypothesis is that there will be no difference in reductions in suicidality at 1-week post-treatment between the combined treatment group and the ketamine only treatment group. The alternative hypothesis is that the combined treatment will result in a greater reduction in suicidal ideation at 1-week post-treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All genders
  • Ages 18 to 70 years
  • Physician order of intranasal esketamine in the UCSD Interventional Psychiatry Clinic
  • Treatment resistant depression diagnosis confirmed by the ordering physician (treatment failure defined as the lack of clinically meaningful response in depression following an antidepressant trial)
  • Ongoing SI present beyond the screening phase of the study (confirmed with Beck SSI score ≥4).
  • Pass the TMS adult safety screening (TASS) questionnaire
  • Voluntary outpatients capable to consent to treatment and seen at the UC San Diego Health Interventional Psychiatry program.
  • Able to adhere to the treatment schedule.

排除标准

  • Previously undergone the Brief Cognitive Behavioral Therapy for Suicide Prevention (BCBT-SP) protocol
  • Currently undergoing an evidence based psychotherapy treatment (according to the policies by the American Psychological Association)
  • Presence of SI prompting emergent hospital stay (SI in which the participant can maintain voluntary and capable as an outpatient, as well as recent suicide attempt, will not be exclusionary)
  • Not capable to consent to treatment or not suitable for outpatient treatment
  • Have a cardiac pacemaker or implanted medication pump; any history of seizure except those therapeutically induced by ECT or a febrile seizure of infancy, cerebral aneurysm, significant head trauma with loss of consciousness for greater than 5 minutes; Have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed.
  • Based on eligibility for Intranasal Esketamine in the UCSD IPP clinic: Lifetime diagnosis of bipolar I or II disorder or schizophrenia spectrum disorder or current diagnosis of a substance use disorder or cognitive disorder documented in the electronic medical records

研究组 & 干预措施

Intranasal Esketamine

Active Comparator

Naturalistic Intranasal Esketamine

干预措施: Naturalistic Intranasal Esketamine (Other)

BCBT-SP + Intranasal Esketamine

Experimental

Brief Cognitive Behavioral Therapy for Suicide Prevention combined with Intranasal Esketamine

干预措施: Naturalistic Intranasal Esketamine (Other)

BCBT-SP + Intranasal Esketamine

Experimental

Brief Cognitive Behavioral Therapy for Suicide Prevention combined with Intranasal Esketamine

干预措施: Brief Cognitive Behavioral Therapy for Suicide Prevention (Behavioral)

结局指标

主要结局

Beck Scale for Suicidal Ideation

时间窗: 1-week post treatment

TMS-EEG N100 peak

时间窗: 1-week post treatment

次要结局

  • Suicidal Ideation Attributes Scale (SIDAS)(1-week post treatment)
  • Columbia Suicide Severity Scale (C-SSRS)(1-week post treatment)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Cory Weissman

Associate Professor

University of California, San Diego

研究点 (1)

Loading locations...

相似试验